Menu Back to 17th-DIA-Japan-Annual-Meeting-2020

Overview

In recent years, while the fourth industrial revolution progresses, various new initiatives on innovation, which lead to novel values or substantial changes in healthcare product research & development, have begun by creation and usage of brand new ideas and technologies such as artificial intelligence, big data and utilization of medical and genome information.

There are two categories of innovation; disruptive innovation, which could bring drastic changes in the way we think and do things, and sustaining innovation, which could bring an improvement of products and services by using technology refinement in the existing platform. Important thing is that; we need to actively learn the cutting-edge technologies supporting various innovations, continuously think how our day-to-day work is going to change in the future, and create skills and mindset which could cope with various new changes. Meanwhile, we would like to encourage key stakeholders in healthcare to step back and think about if the values and changes brought by such innovations would really contribute to health and welfare of patients.

As the theme for the 17th DIA Japan Annual Meeting 2020, we chose the phrase “Beyond Innovation”. With DIA’s mission to provide a neutral platform for discussion, we would like to convene various stakeholder in Industry, government, academia as well as patients, to learn new technologies and initiatives, and discuss what we should eventually aiming for, leading to further facilitate the progress of healthcare innovation.

In this Annual Meeting, we are bringing a new change in the program development process as well; the sessions will be developed based on the submitted abstracts by DIA members, rather than developed by the program committee. We would like to develop a program with a totally new process where participants can openly discuss learnings and challenges based on the living experience of DIA members in healthcare research and development including case studies including successful ones as well as failures. Session themes in both specialties and cross-functional avenues by various stakeholders are greatly welcomed.

Let us realize attractive DIA Japan Annual Meeting by planning and implementing ideal sessions utilizing YOUR creative ideas. We will be waiting for your active participation!

Program Committee

  • Yuji  Kumagai, MD, PhD
    Yuji Kumagai, MD, PhD Professor, Clinical Research Center
    Kitasato University Hospital, Japan
  • Keiichi  Inaizumi, MSc
    Keiichi Inaizumi, MSc Japan Clinical Project Manager, Clinical Operations and Compliance 1
    Pfizer R&D Japan, Japan
  • Taro  Amagasaki, PhD
    Taro Amagasaki, PhD Head, Analytics Japan
    Novartis Pharma K.K., Japan
  • Nobuyuki  Hanamura, PhD, MBA
    Nobuyuki Hanamura, PhD, MBA Senior Director, Clinical Development Strategy & Solutions
    IQVIA Services Japan K.K., Japan
  • Toshiko  Ishibashi, PhD, RN
    Toshiko Ishibashi, PhD, RN Clinical Operation I, Clinical Operation Management
    Ono Pharmaceutical Co., Ltd., Japan
  • Kazuhiko  Ishida, MSc, RPh
    Kazuhiko Ishida, MSc, RPh Risk Management Director, Pharmacovigilance
    Astellas Pharma Inc., Japan
  • Yayoi  Kitawaki, MS
    Yayoi Kitawaki, MS Senior Japan Program Head, Oncology Development Unit, Japan Development
    Novartis Pharma K.K., Japan
  • Yoshiko  Komuro, PhD
    Yoshiko Komuro, PhD Inspector Director, Office of Non-clinical and Clinical Compliance
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takashi  Moriya, PhD, MBA
    Takashi Moriya, PhD, MBA Research & Development Division, Data Sciences, Director
    Janssen Pharmaceutical K.K., Japan
  • Sumimasa  Nagai, MD, PhD
    Sumimasa Nagai, MD, PhD Senior Assistant Professor, Translational Research Center
    The University of Tokyo Hospital, Japan
  • Shinichi  Nishiuma, MD
    Shinichi Nishiuma, MD Executive Director, Head of Medical Affairs, Japan
    Celgene K.K., Japan
  • Mika  Ogasawara
    Mika Ogasawara Quality Lead, Biometrics and Data Management
    Pfizer R&D Japan, Japan
  • Goshi  Ozawa, MS
    Goshi Ozawa, MS Exective officer, RWD dept.
    Real World Data Co., Japan
  • Keiko  Tsumori
    Keiko Tsumori Associate Director, Medical Writing, Regulatory Affairs Area, Japan Development
    MSD K.K., Japan
  • Junichi  Nishino, MSc, RPh
    Junichi Nishino, MSc, RPh Director, Medical Regulatory Affairs Department
    Otsuka Pharmaceutical Co., Ltd., Japan
  • Hironobu  Saito, PhD
    Hironobu Saito, PhD Corporate Officer /Vice President, Oncology Clinical Development Dept., R&D Div.
    Daiichi Sankyo Co., Ltd., Japan
  • Junko  Sato, PhD
    Junko Sato, PhD Director, Office of International Programs
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Takashi  Sato, MSc, PMP
    Takashi Sato, MSc, PMP Manager, Resource Management Group, R&D Planning Department
    Kyowa Kirin Co., Ltd., Japan
  • Atsushi  Tsukamoto, PhD, MSc
    Atsushi Tsukamoto, PhD, MSc
    Daiichi Sankyo Company, Limited, Japan
Load More

Contact us